An extension study to assess BMD [bone mineral density] and bone turnover response to 5 mg daily risedronate [risedronic acid] treatment in women with PMO [postmenopausal osteoporosis].
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2011
At a glance
- Drugs Risedronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors Procter & Gamble
- 24 Mar 2010 Warner Chilcott added as trial sponsor,affiliate as reported by ClinicalTrials.gov.
- 24 Mar 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 15 Jan 2008 New trial record.